Shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) have earned a consensus recommendation of “Hold” from the eight analysts that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $36.00.
Several research firms recently commented on DOVA. BidaskClub lowered shares of Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Raymond James began coverage on shares of Dova Pharmaceuticals in a research note on Wednesday, August 29th. They set an “outperform” rating and a $44.00 price objective for the company. ValuEngine lowered shares of Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Zacks Investment Research lowered shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 16th. Finally, Leerink Swann reduced their price objective on shares of Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating for the company in a research note on Tuesday, September 4th.
In other news, CEO Alex Sapir acquired 21,700 shares of Dova Pharmaceuticals stock in a transaction that occurred on Tuesday, August 14th. The stock was purchased at an average price of $22.83 per share, for a total transaction of $495,411.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steven M. Goldman acquired 5,000 shares of Dova Pharmaceuticals stock in a transaction that occurred on Thursday, June 21st. The shares were purchased at an average price of $30.22 per share, with a total value of $151,100.00. The disclosure for this purchase can be found here. Insiders own 55.50% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of DOVA. BlackRock Inc. raised its stake in shares of Dova Pharmaceuticals by 76.5% during the 2nd quarter. BlackRock Inc. now owns 1,144,920 shares of the company’s stock worth $34,257,000 after acquiring an additional 496,306 shares in the last quarter. Nexthera Capital LP increased its stake in Dova Pharmaceuticals by 44.4% during the 2nd quarter. Nexthera Capital LP now owns 820,348 shares of the company’s stock valued at $24,545,000 after purchasing an additional 252,105 shares in the last quarter. GW&K Investment Management LLC acquired a new position in Dova Pharmaceuticals during the 1st quarter valued at approximately $3,875,000. venBio Select Advisor LLC acquired a new position in Dova Pharmaceuticals during the 1st quarter valued at approximately $3,390,000. Finally, Northern Trust Corp increased its stake in Dova Pharmaceuticals by 154.2% during the 2nd quarter. Northern Trust Corp now owns 163,116 shares of the company’s stock valued at $4,881,000 after purchasing an additional 98,955 shares in the last quarter. Hedge funds and other institutional investors own 36.53% of the company’s stock.
Shares of DOVA traded down $0.12 during mid-day trading on Friday, hitting $24.62. The company’s stock had a trading volume of 78,900 shares, compared to its average volume of 212,956. Dova Pharmaceuticals has a 52-week low of $20.65 and a 52-week high of $37.00. The stock has a market capitalization of $683.62 million, a PE ratio of -17.69 and a beta of 0.04. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.14 and a current ratio of 13.19.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.07). The firm had revenue of $4.58 million for the quarter. equities research analysts forecast that Dova Pharmaceuticals will post -2.78 EPS for the current year.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.